171 related articles for article (PubMed ID: 32440721)
1. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.
Phillips-Chavez C; Watson M; Coward J; Schloss J
Eur J Clin Pharmacol; 2020 Aug; 76(8):1059-1074. PubMed ID: 32440721
[TBL] [Abstract][Full Text] [Related]
2. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
3. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
5. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
6. ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer.
Hua T; Wang RM; Zhang XC; Zhao BB; Fan SB; Liu DX; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34793589
[TBL] [Abstract][Full Text] [Related]
7. Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures.
Yu KH; Levine DA; Zhang H; Chan DW; Zhang Z; Snyder M
J Proteome Res; 2016 Aug; 15(8):2455-65. PubMed ID: 27312948
[TBL] [Abstract][Full Text] [Related]
8. Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
Foote J; Lopez-Acevedo M; Samsa G; Lee PS; Kamal AH; Alvarez Secord A; Havrilesky LJ
Int J Gynecol Cancer; 2018 Feb; 28(2):302-307. PubMed ID: 29360690
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
13. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Davis A; Tinker AV; Friedlander M
Gynecol Oncol; 2014 Jun; 133(3):624-31. PubMed ID: 24607285
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
15. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
17. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
18. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
19. Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment.
Yi X; Liu Y; Zhou B; Xiang W; Deng A; Fu Y; Zhao Y; Ouyang Q; Liu Y; Sun Z; Zhang K; Li X; Zeng F; Zhou H; Chen BT
Biomed Pharmacother; 2021 Jan; 133():111013. PubMed ID: 33227705
[TBL] [Abstract][Full Text] [Related]
20. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
